Crism Therapeutics logo

Crism Therapeutics(LSE) CRTX

Market Cap£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-90%
5 YearN/A
1 Year+18%
1 Month+13%
£0.11
+6.07%
+0.01Today
Crism Therapeutics last closing stock price
MetricPriceDate
Last closeGBX 11.252026-09-10
Crism Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 11.252026-09-03
1 month+12.5%GBX 10.002026-08-11
3 month+7.14%GBX 10.502026-06-12
Year to date+12.5%GBX 10.002025-12-31
1 year+18.42%GBX 9.502025-09-10
Since inception-90.12%GBX 1.142006-03-15

Crism Therapeutics Financials at a Glance

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£2.52M

EPS (TTM)

-£0.05

P/E Ratio

-2.16

Dividend

£0.00

Beta (Volatility)

0.17 (Low)

Price

£0.11

Volume

4,468

Open

£0.11

Previous Close

£0.11

Daily Range

£0.11 - £0.11

52-Week Range

£0.08 - £0.18

Estimated Earnings Date

Sep 23, 2026

CRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Crism Therapeutics

Amur Minerals Corporation is focused on the exploration and advancement of mineral resources in the Russian Far East. The company primarily targets reserves of nickel, copper, cobalt, platinum, palladium, gold, and silver, with its flagship asset being the Kun-Manie nickel-copper sulphide venture.

Products and Services
  • Exploration of nickel and copper resources
  • Assessment and procurement of mineral reserves
  • Development of mining projects in the Russian Far East
Growth Outlook
  • Kun-Manie project spans 36 square kilometers, indicating significant resource potential
  • Strategic focus on high-demand metals aligns with global market trends
  • Ongoing exploration efforts aim to enhance resource estimates and project viability
Financial Highlights
  • Recent quarterly net income of -$2.28 million reflects ongoing operational challenges
  • Cash and cash equivalents stood at $4.38 million as of June 30, 2023
  • Trailing twelve-month dividend yield of 14.47% indicates potential for income generation
Amur Minerals Corporation operates in the industrial materials sector, with a strong emphasis on nickel and copper exploration. The company's flagship Kun-Manie project is a significant asset, providing a foundation for future growth. Despite recent financial challenges, including a net loss in the latest quarter, the company maintains a solid cash position, which is crucial for ongoing operations and exploration activities. The high dividend yield may attract income-focused investors, while the strategic focus on high-demand metals positions the company well for future market opportunities.
AI Generated • Sep 6, 2026

Industry

Biotechnology

CEO

Andrew James Webb

Headquarters

Road Town, TO, VG

CRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-139.63%

Return on Capital

-148.94%

Return on Assets

-106.27%

Earnings Yield

-46.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

79.19M

Volume

4.47K

Avg. Volume

275.70K

Financials (TTM)

Gross Profit

-£129.02K

Operating Income

-£3.02M

EBITDA

-£2.69M

Operating Cash Flow

-£2.91M

Capital Expenditure

£1.00

Free Cash Flow

-£2.91M

Cash & ST Invst.

£1.13M

Total Debt

£0.00

Crism Therapeutics Performance Analysis

Crism Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 45,000N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
Crism Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Crism Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.2857.3%
20232023-12-31GBP -0.02-92.1%
20242024-12-31GBP -0.02-15.6%
20252025-12-31GBP -0.05176.2%
Crism Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3079.0%
Q42024-12-31-970.6%
Q22025-06-30-53.8%
Q42025-12-3115.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£106.00K

-1497.7%

Gross Margin

0.00%

N/A

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.23M

N/A

Employees

4

N/A

Net Income

-£973.00K

-1161.9%

EBITDA

-£1.19M

-2093.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.13M

-74.3%

Total Debt

£0.00

N/A

Accounts Receivable

£242.00K

+1482.0%

Inventory

£0.00

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£0.00

-100.0%

Return on Assets

-1.06%

N/A

Return on Invested Capital

-1.49%

N/A

Free Cash Flow

-£1.10M

-17473.4%

Operating Cash Flow

-£1.10M

-28855.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRX.LTissue Regenix Group plc
£0.07+0.00%
PRM.LProteome Sciences plc
£0.02+9.23%
N4P.LN4 Pharma Plc
£0.00+0.00%
TCF.LTheracryf Plc
£0.00-8.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
ACVAACV Auctions
$10.43+0.44%
TNONTenon Medical
$7.19+0.36%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.63+0.06%
ORCLOracle
$156.35+0.02%

Questions About CRTX

What is the current price of Crism Therapeutics?

Crism Therapeutics is trading at £0.11 per share.

What is the 52-week range for Crism Therapeutics?

Over the past 52 weeks, Crism Therapeutics has traded between £0.08 and £0.18.

How much debt does Crism Therapeutics have?

As of the most recent reporting period, Crism Therapeutics reported total debt of £0.00.

How much cash does Crism Therapeutics have on hand?

Crism Therapeutics reported £1.13M in cash and cash equivalents in its most recent financial results.

What is Crism Therapeutics’s dividend yield?

Crism Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.